SEC Tracker
Get the app

Retension Pharmaceuticals RTSN

Retension Pharmaceuticals Eric Keller filed SCHEDULE 13D

Ownership stake disclosure by Eric L. Keller

Form
Schedule 13D
Filed
Importance
Notable
  1. Eric Keller beneficially owns 598,598 shares (7.07%)
  2. Acquired 2,500,000 shares in 2023
  3. Purchased 50,000 Series A Preferred Stock in 2023
  4. Converted Series A/B Preferred Stock to Common Stock in 2026

Written from the Schedule 13D on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Retension Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX